![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/norgine-bv-submits-marketing-authorisation-application-via-project-orbis-for-eflornithine-difluoromethylornithine-dfmo-in-high-risk-neuroblastoma-302116815.html
https://www.prnewswire.com/news-releases/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia-302099840.html
https://www.prnewswire.com/news-releases/fennec-pharmaceuticals-and-norgine-enter-into-exclusive-licensing-agreement-to-commercialize-pedmarqsi-in-europe-australia-and-new-zealand-302090953.html
https://www.globenewswire.com/news-release/2024/03/18/2847436/0/en/Fennec-Pharmaceuticals-and-Norgine-Enter-into-Exclusive-Licensing-Agreement-to-Commercialize-PEDMARQSI-in-Europe-Australia-and-New-Zealand.html
https://www.prnewswire.com/news-releases/norgine-strengthens-senior-leadership-with-the-appointment-of-saulo-martiniano-as-chief-operating-officer-301921856.html
https://www.prnewswire.com/news-releases/norgine-announces-closing-of-investment-from-goldman-sachs-asset-management-301703371.html
https://www.prnewswire.com/news-releases/norgine-bv-and-us-worldmeds-enter-into-exclusive-licensing-agreement-to-commercialise-dfmo-eflornithine-in-europe-commonwealth-of-independent-states-australia-and-new-zealand-301339773.html
https://www.prnewswire.com/news-releases/norgine-bv-and-us-worldmeds-enter-into-exclusive-licensing-agreement-to-commercialise-dfmo-eflornithine-in-europe-commonwealth-of-independent-states-australia-and-new-zealand-301339773.html
https://www.prnewswire.com/news-releases/norgine-bv-and-us-worldmeds-enter-into-exclusive-licensing-agreement-to-commercialise-dfmo-eflornithine-in-europe-commonwealth-of-independent-states-australia-and-new-zealand-301339773.html